Ascendis Pharma A/S Ordinary Share ASND

Ascendis Pharma A/S es una empresa con sede en Dinamarca que fabrica productos farmacéuticos. La empresa produce productos para el tratamiento de la deficiencia de hormona del crecimiento, endocrinología, trastornos del sistema nervioso central, enfermedades infecciosas y diabetes. La empresa opera a nivel global a través de sus subsidiarias: Ascendis Pharma GmbH (Alemania), Ascendis Pharma, Inc. (Delaware, Estados Unidos), Ascendis Pharma Endocrinology, Inc. (Delaware, Estados Unidos), Ascendis Pharma, División de Oftalmología A/S (Dinamarca), Ascendis Pharma, División de Endocrinología A/S (Dinamarca), Ascendis Pharma Bone Diseases A/S (Dinamarca), Ascendis Pharma Growth Disorders A/S (Dinamarca) y Ascendis Pharma Oncology Division A/S (Dinamarca).

• Zacks Investment Research 16 sept

  BioMarin Stops Voxzogo Development for Noonan Syndrome

  BioMarin Pharmaceutical announced it is discontinuing development of Voxzogo for Noonan syndrome due to study feasibility and treatment landscape concerns, though not due to safety or efficacy issues. Despite this setback, Voxzogo generated $472 million in first-half 2026 sales (up 9% YoY) and is on track to achieve blockbuster status with expected 2026 sales of $1.00-$1.05 billion. The drug faces increasing competition from Ascendis Pharma's Yuviwel and BridgeBio's infigratinib, though BioMarin secured a royalty-bearing settlement with Ascendis.

  

• GlobeNewswire Inc. 14 sept

  Ascendis Announces Planned $400 Million Share Repurchase Program

  Ascendis Pharma A/S announced that its Board of Directors has authorized a $400 million share repurchase program. The company will execute purchases through various methods including open market transactions and accelerated share repurchase agreements, with timing and amounts determined by market conditions and share price.

  

• Zacks Investment Research 3 sept

  How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

  BioMarin settled a patent dispute with Ascendis Pharma over the achondroplasia drug Yuviwel, converting a competitive threat into a royalty stream. Under the agreement, BioMarin will receive 20% royalties on U.S. Yuviwel sales and 18% in the EU, Brazil, and South Korea through May 2030. While this monetizes competition, BioMarin still faces market pressure from Yuviwel and potential future competitors like BridgeBio's infigratinib.

  

• The Motley Fool 30 jun

  Big Pharma Has a Case of Merger Mania

  The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

  

• Benzinga 12 jun

  Why Is Ascendis Pharma Stock Gaining Friday?

  Ascendis Pharma reported positive five-year results from its PaTH Forward trial for TransCon PTH (YORVIPATH), showing sustained efficacy and safety in treating adult hypoparathyroidism. The therapy demonstrated that 82% of patients met composite response endpoints, with 88% maintaining normal calcium levels and 96% achieving independence from active vitamin D therapy. The drug showed durable kidney benefits and a consistent safety profile with no new safety signals. ASND stock rose 3.60% to $223.37 on the news.